Microbial risk in pharmaceutical process is not limited to living microorganisms and intact microbial cells. Subcellular components from microorganisms remaining from the production process can be source of pyrogens, compromising product quality and patient safety as these substances are not eliminated by classical filtration or sterilization steps. The monocyte activation test performed with the PyroMAT® System detects endotoxin and non-endotoxin pyrogens.
Key Topics
- The microbial risk in pharmaceutical process cannot be limited to viable microorganisms
- Performing an endotoxin test for product release may not be enough to ensure patient safety
- MAT can help you to assess the pyrogenic risk resulting from your production process
- The PyroMAT® System has shown its ability to detect a panel of non-endotoxin pyrogen contaminants
Speakers
Mathilde Arnault
Merck
Research Scientist
Webinar Information
Microbiological testing
- Pyrogen testing
Duration:24min
語言:English
會話 1:提出 April 9, 2019
登入以繼續
若要繼續閱讀,請登入或建立帳戶。
還沒有帳戶?